Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial

Neuromuscular Disorders

Volumn 21, Issue 6, 2011, Pages 396-405

  Buyse, Gunnar M ^a   Goemans, Nathalie ^a   van den Hauwe, Marleen ^a   Thijs, Daisy ^a   de Groot, Imelda J M ^b   Schara, Ulrike ^c   Ceulemans, Berten ^d   Meier, Thomas ^e   Mertens, Luc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Santhera Pharmaceuticals   (Switzerland)

Author keywords

Cardiac; Cardiomyopathy; Duchenne; Idebenone; Muscular dystrophy; Respiratory function; Treatment

Indexed keywords

CATENA; IDEBENONE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL RESPIRATORY SOUND; ADOLESCENT; ARTICLE; BRONCHITIS; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; FEMUR FRACTURE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MALE; MIGRAINE; MUSCLE STRENGTH; MYCOSIS; PATIENT ATTITUDE; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFECTION; RHINITIS; SCHOOL CHILD; SIDE EFFECT; THORAX PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ADOLESCENT; ANTIOXIDANTS; CHILD; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME; TROPONIN I; UBIQUINONE; VITAL CAPACITY;

EID: 79956111449     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.02.016     Document Type: Article

References (40)

1. Emery A.E.H. Clinical features. Duchenne muscular dystrophy 2003, 6-45. Oxford University Press. A.E.H. Emery (Ed.).
2. Inkley S.R., Oldenburg F.C., Vignos P.J. Pulmonary function in Duchenne muscular dystrophy related to stage of disease. Am J Med 1974, 56:297-306.
3. Rideau R.Y., Jankowski L.W., Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve 1981, 4:155-164.
4. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(Suppl.):S70-S92.
5. Muntoni F. Cardiomyopathy in muscular dystrophies. Curr Opin Neurol 2003, 16:577-583.
6. Finsterer J., Stollberger C. The heart in human dystrophinopathies. Cardiology 2003, 99:1-19.
7. Townsend D., Yasuda S., Chamberlain J., Metzger J.M. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends Cardiovasc Med 2009, 19:50-55.
8. Giatrakos N., Kinali M., Stephens D., Dawson D., Muntoni F., Nihoyannopoulos P. Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne's muscular dystrophy: relationship to clinical outcome. Heart 2006, 92:840-842.
9. Mertens L., Ganame J., Claus P., et al. Early regional myocardial dysfunction in young patients with Duchenne muscular dystrophy. J Am Soc Echocardiogr 2008, 21:1049-1054.
10. Ashford M.W., Liu W., Lin S.J., et al. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation 2005, 112:2462-2467.
11. Chetboul V., Escriou C., Tessier D., et al. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. Eur Heart J 2004, 25:1934-1939.
12. Bushby K., Finkel R., Birnkrant D., et al. DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
13. Zs-Nagy I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. Arch Gerontol Geriatr 1990, 11:177-186.
14. Gillis J.C., Benfield P., McTavish D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 1994, 5:133-152.
15. Buyse G.M., Van der Mieren G., Erb M., et al. Long-term placebo-controlled study showing phenotypic correction of dystrophin-deficiency in the mdx mouse by SNT-MC17/idebenone. Eur Heart J 2009, 30:116-124.
16. Weidemann F., Eyskens B., Jamal F., et al. Quantification of regional left and right ventricular radial and longitudinal function in healthy children using ultrasound-based strain rate and strain imaging. J Am Soc Echocardiogr 2002, 15:20-28.
17. Koopman L.P., Slorach C., Hui W., et al. Comparison between different speckle tracking and color tissue Doppler techniques to measure global and regional myocardial deformation in children. J Am Soc Echocardiogr 2010, 23:919-928.
18. Mori K., Manabe T., Nii M., Hayabuchi Y., Kuroda Y., Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 2002, 23:160-166.
19. Matsumura T., Saito T., Fujimura H., Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev 2007, 29:496-501.
20. Domènech-Clar R., Lopez-Andreu J.A., Compte-Torrero L., et al. Maximal static respiratory pressures in children and adolescents. Pediatr Pulmonol 2003, 35:126-132.
21. Godfrey S., Kamburoff P.L., Nairn J.R. Spirometry, lung volumes and airway resistance in normal children aged 5 to 18years. Br J Dis Chest 1970, 64:15-24.
22. Finder J.D., Birnkrant D., Carl J., et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004, 170:456-465.
23. Escolar D.M., Henricson E.K., Mayhew J., et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 2001, 24:787-793.
24. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology 1976, US Department of Health, Education and Welfare, Rockville, MD. W. Guy (Ed.).
25. Bodmer M., Vankan P., Dreier M., Kutz K.W., Drewe J. Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol 2009, 65:493-501.
26. Ganame J., Claus P., Uyttebroeck A., et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Eechocardiogr 2007, 20:1351-1358.
27. Greenberg N.L., Firstenberg M.S., Castro P.L., et al. Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility. Circulation 2002, 105:99-105.
28. Hor K.N., Wansapura J., Markham L.W., et al. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol 2009, 53:1204-1210.
29. Hagenbuch S.C., Gottliebson W.M., Wansapura J., et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol 2010, 105:1451-1455.
30. Wansapura J.P., Hor K.N., Mazur W., et al. Left ventricular T2 distribution in Duchenne muscular dystrophy. J Cardiovasc Magn Reson 2010, 12:14-22.
31. Puchalski M.D., Williams R.V., Askovich B., et al. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?. Int J Cardiovasc Imaging 2009, 25:57-63.
32. Phillips M.F., Quinlivan R.C., Edwards R.H., Calverley P.M. Changes in spirometry over time as prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001, 15:2191-2194.
33. Suarez A.A., Pessolano F.A., Monteiro S.G., et al. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil 2002, 81:506-511.
34. Vincken W.G., Elleker M.G., Cosio M.G. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. Am J Med 1987, 83:673-680.
35. Hahn A., Bach J.R., Delaubier A., Renardel-Irani A., Guillou C., Rideau Y. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne mucular dystrophy. Arch Phys Med Rehabil 1997, 78:1-6.
36. Suno M., Nagaoka A. Inhibition of lipid peroxidation by a novel compound, idebenone (CV 2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 1984, 125:1046-1052.
37. Sugiyama Y., Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1995, 184:48-51.
38. Rodriguez M.C., Tarnopolsky M.A. Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 2003, 34:1217-1220.
39. Nakae Y., Stoward P.J., Kashiyama T., et al. Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice. J Mol Histol 2004, 35:489-499.
40. Tidball J.G., Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007, 578:327-336.